Pharmacokinetics and Classification
Sulfalene belongs to resorptive sulfonamides. This means the drug is characterized by good gastrointestinal absorption and exerts a systemic effect throughout the body, rather than acting solely within the intestinal lumen.
A key pharmacokinetic feature of Sulfalenum is its very slow elimination from the body. This is caused by intensive reabsorption of the drug molecules in the renal tubules.
Due to this property, the drug occupies a special place in the classification of sulfonamides based on their half-life ($t_{1/2}$):
- Short-acting ($t_{1/2} < 10$ h): Sulfanilamide (streptocide), Sulfathiazole, Sulfaethidole, Sulfacarbamide, Sulfadimidine.
- Intermediate-acting ($t_{1/2}$ 10–24 h): Sulfadiazine, Sulfamethoxazole.
- Long-acting ($t_{1/2}$ 24–48 h): Sulfadimethoxine, Sulfamonomethoxine, Sulfamethoxypyridazine.
- Ultra-long-acting ($t_{1/2} > 48$ h): Sulfalene.
Dosing Regimens and Formulations
The drug is available in 0.2 g tablets. The dosing regimen strictly depends on the nature of the disease and the rate of progression of the infectious process.
For acute and rapidly progressing infections: The drug is administered orally daily. On the first day of therapy, a loading dose is given — 1.0 g per day — to rapidly establish a therapeutic concentration in the blood. On subsequent days, the dose is reduced to a maintenance dose of 0.2 g per day.
For chronic and prolonged infections: Given its ultra-long half-life, the dosing schedule changes:
- Oral: administered only once every 7–10 days.
- Parenteral (intravenous or intramuscular): administered once daily.
Combined Antifolate Therapy
In modern pharmacology, Sulfalene is often used in the context of combination antifolate drugs.
The core principle of this therapy is the synergistic combination of a sulfonamide and pyrimethamine. This blocks microbial folic acid synthesis at two different sequential steps simultaneously, which significantly enhances the antimicrobial effect and reduces the risk of resistance.
Key combinations in this group include:
- Sulfadoxine + Pyrimethamine (a well-known representative is Fansidar).
- Sulfalene + Pyrimethamine.
Adverse Effects
When prescribing Sulfalenum, clinicians must be aware of the risk of severe allergic reactions. The most severe and life-threatening adverse effect is Stevens–Johnson syndrome.
This is a severe form of erythema multiform exudativum accompanied by blistering of the skin and mucous membranes. The development of this syndrome requires immediate discontinuation of the drug and emergency medical care.